Clinical Trial Update: Quality of Life in Chinese Postmenopausal HR(+) Early Breast Cancer (EBC) Patients During Adjuvant Aromatase Inhibitors(AIs) Treatment

View source ↗

Summary

A completed clinical trial assessing quality of life in Chinese postmenopausal hormone receptor–positive early breast cancer patients during adjuvant aromatase …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• ARIMIDEX (anastrozole)
• Aromasin (exemestane)
• FEMARA (letrozole)

Snippet

Sponsor: AstraZeneca | Conditions: Breast Cancer | Status: COMPLETED